164 related articles for article (PubMed ID: 16792833)
1. Hormone replacement therapy and mammographic screening outcomes in Western Australia.
Crouchley K; Wylie E; Khong E
J Med Screen; 2006; 13(2):93-7. PubMed ID: 16792833
[TBL] [Abstract][Full Text] [Related]
2. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
3. Type and duration of exogenous hormone use affects breast cancer histology.
Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES
Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
[TBL] [Abstract][Full Text] [Related]
4. Duration of hormone replacement therapy, breast tumour size and grade in a screening programme.
Gertig DM; Erbas B; Fletcher A; Amos A; Kavanagh AM
Breast Cancer Res Treat; 2003 Aug; 80(3):267-73. PubMed ID: 14503799
[TBL] [Abstract][Full Text] [Related]
5. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
[TBL] [Abstract][Full Text] [Related]
6. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
Khoo SK; Chick P
Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and accuracy of mammographic screening.
Kavanagh AM; Mitchell H; Giles GG
Lancet; 2000 Jan; 355(9200):270-4. PubMed ID: 10675074
[TBL] [Abstract][Full Text] [Related]
8. Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis.
Fletcher AS; Erbas B; Kavanagh AM; Hart S; Rodger A; Gertig DM
Breast; 2005 Jun; 14(3):192-200. PubMed ID: 15927828
[TBL] [Abstract][Full Text] [Related]
9. Urban-rural differences in the management of screen-detected invasive breast cancer and ductal carcinoma in situ in victoria.
Kok DL; Chang JH; Erbas B; Fletcher A; Kavanagh AM; Henderson MA; Gertig DM
ANZ J Surg; 2006 Nov; 76(11):996-1001. PubMed ID: 17054549
[TBL] [Abstract][Full Text] [Related]
10. Tumour size at detection according to different measures of mammographic breast density.
Nickson C; Kavanagh AM
J Med Screen; 2009; 16(3):140-6. PubMed ID: 19805755
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
12. Age-specific interval breast cancers in New South Wales and meta-analysis of studies of women aged 40-49 years.
Taylor R; Page A; Bampton D; Estoesta J; Rickard M
J Med Screen; 2004; 11(4):199-206. PubMed ID: 15563775
[TBL] [Abstract][Full Text] [Related]
13. Likelihood of additional work-up among women undergoing routine screening mammography: the impact of age, breast density, and hormone therapy use.
Carney PA; Kasales CJ; Tosteson AN; Weiss JE; Goodrich ME; Poplack SP; Wells WS; Titus-Ernstoff L
Prev Med; 2004 Jul; 39(1):48-55. PubMed ID: 15207985
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy, percent mammographic density, and sensitivity of mammography.
Kavanagh AM; Cawson J; Byrnes GB; Giles GG; Marr G; Tong B; Gertig DM; Hopper JL
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1060-4. PubMed ID: 15894653
[TBL] [Abstract][Full Text] [Related]
15. Minority report - false negative breast assessment in women recalled for suspicious screening mammography: imaging and pathological features, and associated delay in diagnosis.
Ciatto S; Houssami N; Ambrogetti D; Bonardi R; Collini G; Del Turco MR
Breast Cancer Res Treat; 2007 Sep; 105(1):37-43. PubMed ID: 17115112
[TBL] [Abstract][Full Text] [Related]
16. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment.
Ursic-Vrscaj M; Bebar S
Eur J Surg Oncol; 1999 Apr; 25(2):146-51. PubMed ID: 10218456
[TBL] [Abstract][Full Text] [Related]
17. The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?
Biesheuvel C; Czene K; Orgeás CC; Hall P
Cancer Epidemiol; 2011 Dec; 35(6):545-50. PubMed ID: 21470933
[TBL] [Abstract][Full Text] [Related]
18. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
19. Interval cancer incidence and episode sensitivity in the Norrbotten Mammography Screening Programme, Sweden.
Bordás P; Jonsson H; Nyström L; Lenner P
J Med Screen; 2009; 16(1):39-45. PubMed ID: 19349530
[TBL] [Abstract][Full Text] [Related]
20. Estimating mean sojourn time and screening test sensitivity in breast cancer mammography screening: new results.
Weedon-Fekjaer H; Vatten LJ; Aalen OO; Lindqvist B; Tretli S
J Med Screen; 2005; 12(4):172-8. PubMed ID: 16417693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
